

**2021 Cardiology Pharmacy Specialty Recertification Literature Study:  
Module 1A: Updates in Atrial Fibrillation and Antithrombotics in Valvular and  
Peripheral Vascular Disease**

**Learning Objectives and Articles**

**Module 1A: Updates in Atrial Fibrillation and Antithrombotics in Valvular and Peripheral Vascular Disease**

**Universal Activity Number: 0204-9999-21-979-H01-P**

**Contact Hours: 4.00**

**Activity Type: Application-Based**

This module focuses on updates in atrial fibrillation and antithrombotics in valvular and peripheral vascular disease.

Bonaca MP, Bauersachs RM, Anand SA, et al. Rivaroxaban in peripheral artery disease after revascularization. *N Engl J Med.* 2020; 382:1994-2004.

Learning Objectives:

- Describe the Vascular Outcomes Study of ASA (acetylsalicylic acid) Along with Rivaroxaban in Endovascular or Surgical Limb Revascularization for PAD (peripheral artery disease) [VOYAGER-PAD] by Bonaca and colleagues
- Develop recommendations for the use of antithrombotic therapy in patients with symptomatic peripheral artery disease (PAD) who have undergone lower-extremity revascularization

Kirchhof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation. *N Engl J Med.* 2020; 383:1305-16.

Learning Objectives:

- Describe the Early Treatment of Atrial Fibrillation for Stroke Prevention Trial (EAST-AFNET 4) by Kirchhof and colleagues of early rhythm-control therapy for patients with atrial fibrillation
- Develop recommendations for the use of rhythm-control therapy in patients with atrial fibrillation

Dangas GD, Tijssen JGP, Wohrle J, et al. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. *N Engl J Med.* 2020; 382:120-129.

Learning Objectives:

- Describe the Global Study Comparing a Rivaroxaban-based Antithrombotic Strategy to an Antiplatelet-based Strategy after Transcatheter Aortic Valve Replacement to Optimize Clinical Outcomes (GALILEO) study by Dangas and colleagues
- Develop recommendations for the use of antithrombotic therapy after successful transcatheter aortic-valve replacement (TAVR) for aortic-valve stenosis

Nijenhuis VJ, Brouwer J, Delewi R et al. Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation. *N Engl J Med.* 2020; 382:1696-1707.

Learning Objectives:

- Describe cohort B of the POPular TAVI study by Nijenhuis and colleagues of anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation (TAVI) in patients with symptomatic severe aortic stenosis and an indication for use of long-term anticoagulation
- Develop recommendations for the use of antithrombotic therapy after transcatheter aortic-valve implantation (TAVI) in patients with symptomatic severe aortic stenosis and an indication for use of long-term anticoagulation

Brouwer J, Nijenhuis VJ, Delewi R et al. Aspirin with or without clopidogrel after transcatheter aortic-valve implantation. *N Engl J Med.* 2020; 383:1447-1457.

Learning Objectives:

- Describe cohort A of the POPular TAVI study by Brouwer and colleagues of aspirin with or without clopidogrel after transcatheter aortic-valve implantation (TAVI) in patients with symptomatic severe aortic stenosis without an indication for use of long-term anticoagulation
- Develop recommendations for the use of antiplatelet therapy after transcatheter aortic-valve implantation (TAVI) in patients with symptomatic severe aortic stenosis without an indication for use of long-term anticoagulation